Oxford BioDynamics Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University

Author's Avatar
Oct 28, 2020
Article's Main Image

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing personalized medicine tests based on 3D genomic biomarkers, has signed a Human Material and Data Transfer Agreement with Oregon Health & Science University (OHSU) as part of its EpiSwitch™ COVID-19 disease severity test program.